High Court confirms patentability of methods of medical treatment

Consideration of what constitutes patentable subject matter has been a recurring theme in both Australian and US courts this year: In Australia, the Federal Court has considered the patentability of genetic/biological material (Cancer Voices Australia v Myriad Genetics Inc) as well as software and business methods (Research Affiliates LLC v Commissioner of Patents) In the US, the Supreme

Gene patents are alive and well in Australia

In its long-awaited landmark decision, on 15 February 2013 our Federal Court confirmed that isolated genetic/biological material is patentable subject matter in Australia (Cancer Voices Australia v Myriad Genetics Inc. [2013] FCA 65 ). Gene patents have been the subject of two Senate Inquiries and Private Members’ Bills. In all instances, the arguments in support